Skip to main
PAVM

PAVmed (PAVM) Stock Forecast & Price Target

PAVmed (PAVM) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PAVmed Inc. has demonstrated solid growth in its EsoGuard testing volume, processing 2,841 tests in Q3, reflecting an increase from previous quarters, indicating a positive trend in its diagnostic business. The company's current valuation is considered attractive, balancing its inherent risks with substantial upside potential, suggesting a favorable investment scenario. Additionally, the expected significant growth in PAVmed's commercialized products, including EsoGuard, Esocheck, and the Veris Cancer Care Platform, positions the company for continued success in the medical technology sector in the near future.

Bears say

PAVmed Inc has reported a pro forma net loss of $0.8 million, highlighting ongoing financial struggles, as this figure is significantly below the consensus estimate range for earnings per share, which was between $(0.13) and $(0.25). Additionally, a decline in the number of EsoGuard tests processed, from 3,034 in Q1 to 2,756 in Q2, raises concerns about demand and growth potential in this critical segment of the business. The company's early-stage products, including the Lucid business and Veris platform, contribute to low current revenue levels, while various risks, including liquidity challenges and regulatory hurdles, further underscore the negative outlook on the stock.

PAVmed (PAVM) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PAVmed (PAVM) Forecast

Analysts have given PAVmed (PAVM) a Strong Buy based on their latest research and market trends.

According to 1 analysts, PAVmed (PAVM) has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PAVmed (PAVM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.